Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

作者：Carolyn Bolton‐Moore, Kristin Baltrusaitis, Brookie M. Best, Jack Moye, Ellen Townley, Avy Violari, Barbara Heckman, Sarah Buisson, Rodica M Van Solingen-Ristea, Edmund V. Capparelli, Mark A. Marzinke, Elizabeth D. Lowenthal, S. M. Ward, Chelsea Krotje, Ryan O. Milligan, Allison L. Agwu, Jenny Huang, S.Y. Amy Cheung, Cynthia McCoig, Dwight E. Yin, Gilly Roberts, Herta Crauwels, Veerle Van Eygen, Sara Zabih, Gaerolwe Masheto, Pradthana Ounchanum, Linda Aurpibul, Violet Korutaro, Aditya H. Gaur, Kyle Whitson, Michael Whitton, Conn M. Harrington, Faeezah Patel, Mary E. Paul, Sherika Hanley, Kati Vandermeulen, Yu-Wei Lin, Isabelle Deprez, Kelong Han, Susan L. Ford, Jon W. Collins · 发表于：The Lancet HIV · 年份：2025 · DOI：10.1016/s2352-3018(24)00344-8 · 被引用次数：12 · 研究领域：HIV-related health complications and treatments、HIV/AIDS Research and Interventions、HIV/AIDS drug development and treatment